KemPharm, Inc. Announces Entering Into an Exclusive Supply Agreement With Johnson Matthey Inc. for KP201

KemPharm, Inc. today announced that it has entered into an exclusive Supply Agreement with Johnson Matthey Inc., for the manufacture of the active pharmaceutical ingredient , KP201, KemPharm's novel hydrocodone prodrug for acute pain. Â KP201 was identified utilizing KemPharm's proprietary ligand activated therapy approach. Â In preclinical [...]